Efficacy of re-challenging metastatic renal cell carcinoma with mTOR inhibitors

Acta Oncol. 2011 Oct;50(7):1135-6. doi: 10.3109/0284186X.2011.592149. Epub 2011 Jul 5.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Benzimidazoles / administration & dosage
  • Carcinoma, Renal Cell* / drug therapy
  • Carcinoma, Renal Cell* / secondary
  • Everolimus
  • Humans
  • Indoles / administration & dosage
  • Kidney Neoplasms* / drug therapy
  • Kidney Neoplasms* / pathology
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / secondary
  • Male
  • Middle Aged
  • Neoplasm Metastasis
  • Pyrroles / administration & dosage
  • Quinolones / administration & dosage
  • Sirolimus / administration & dosage
  • Sirolimus / analogs & derivatives
  • Sunitinib
  • TOR Serine-Threonine Kinases / antagonists & inhibitors*

Substances

  • 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
  • Antineoplastic Agents
  • Benzimidazoles
  • Indoles
  • Pyrroles
  • Quinolones
  • Everolimus
  • TOR Serine-Threonine Kinases
  • Sunitinib
  • Sirolimus